Press Release Archive

Note: prior to September, 2016, Proclara Biosciences was known as NeuroPhage Pharmaceuticals.

 

NeuroPhage's GAIM Technology Chosen as 'Top Project to Watch' for the Therapeutic Area Partnerships Conference 
November 14, 2014

NeuroPhage Appoints Industry Veteran Franz Hefti, PhD, President/COO 
November 4, 2014

NeuroPhage Discovers GAIM-changing Molecules to Combat Alzheimer's Disease and Other Neurodegenerative Disorders 
April 22, 2014

NeuroPhage, Inc. Raises $17 Million in Series D Financing 
March 25, 2014

NeuroPhage Awarded Second Grant from Michael J. Fox Foundation for Parkinson's Disease Research 
December 19, 2013

NeuroPhage to Participate in World's First G8 Dementia Summit 
December 3, 2013

Neurophage, Inc. Raises $6.4 Million in Additional Financing 
May 6, 2013

Antitope Ltd., Announces Protein Deimmunisation Research Agreement with NeuroPhage Pharmaceuticals, Inc. 
January 17, 2013

NeuroPhage Reports Beneficial Effects of its Drug Candidate in a Preclinical Study of Parkinson's Disease Funded by The Michael J. Fox Foundation
October 17, 2012

NeuroPhage extends Series B to $21.4M 
March 8, 2012

NeuroPhage Receives Michael J. Fox Foundation Funding for Parkinson's Disease Research 
February 16, 2012

NeuroPhage Selected as Top 10 CNS Biotech Company at the Upcoming 6th Annual Therapeutics Area Partnerships Conference 
November 16, 2011

NeuroPhage Pharmaceuticals closes $12.4M Series B round 
March 1, 2011

NeuroPhage Raises a $7 Million Series A Financing to Develop a Unique Disease-Modifying Approach to Treating Alzheimer's and Other Neurodegenerative Disorders 
February 21, 2008

Dr. Beka Solomon Named to Scientific American's SciAm 50 Leading Innovators
December 16, 2007